ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020

Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?

Daniel F Alvarez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.